99mTc-PHG102

99mTc-PHG102 is a nanobody-based **radiopharmaceutical probe** that selectively targets **Claudin 18.2 (CLDN18.2)**, a biomarker highly expressed in certain types of gastric cancer. It consists of the nanobody PHG102 conjugated to the gamma-emitting radioisotope technetium-99m (^99m^Tc), enabling targeted SPECT/CT imaging of CLDN18.2-positive tumors. The probe is designed for **non-invasive visualization and quantification of CLDN18.2 expression**, facilitating patient screening for CLDN18.2-targeted therapies and monitoring tumor status. The mechanism involves specific binding of the nanobody to the CLDN18.2 epitope, with high affinity (K~d~ ≈ 24 nM), resulting in pronounced tumor uptake and rapid metabolism in non-target tissues. In clinical and preclinical studies, 99mTc-PHG102 demonstrated effective and selective tumor imaging, high radiochemical purity and stability, and a safe radiation dose profile. It is positioned as a companion diagnostic agent for personalized management of CLDN18.2-expressing gastric cancers[1][3][4][7][21].

Brand names

99mTc-PHG102

Other names

99mTc-PHG102[^99m^Tc]Tc-PHG102technetium-99m labeled PHG102technetium99m labeled PHG102technetium 99m labeled PHG102